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Summary
 
After culture in interleukin (IL)-2, natural killer (NK) cells acquire an increased capability of
mediating non–major histocompatibility complex (MHC)–restricted tumor cell lysis. This may
reflect, at least in part, the de novo expression by NK cells of triggering receptors involved in cy-
tolysis. In this study we identified a novel 44-kD surface molecule (NKp44) that is absent in
freshly isolated peripheral blood lymphocytes but is progressively expressed by all NK cells in vitro
after culture in IL-2. Different from other markers of cell activation such as CD69 or VLA.2,
NKp44 is absent in activated T lymphocytes or T cell clones. Since NKp44 was not detected in
any of the other cell lineages analyzed, it appears as the first marker specific for activated human
NK cells. Monoclonal antibody (mAb)–mediated cross-linking of NKp44 in cloned NK cells
resulted in strong activation of target cell lysis in a redirected killing assay. This data indicated
that NKp44 can mediate triggering of NK cell cytotoxicity. mAb-mediated masking of NKp44
resulted in partial inhibition of cytolytic activity against certain (Fc
 
g
 
R-negative) NK-suscepti-
ble target cells. This inhibition was greatly increased by the simultaneous masking of p46, an-
other recently identified NK-specific triggering surface molecule. These data strongly suggest
that NKp44 functions as a triggering receptor selectively expressed by activated NK cells that,
together with p46, may be involved in the process of non-MHC-restricted lysis. Finally, we
show that p46 and NKp44 are coupled to the intracytoplasmic transduction machinery via the
association with CD3
 
z
 
 or KARAP/DAP12, respectively; these associated molecules are ty-
rosine phosphorylated upon NK cell stimulation.
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H
 
uman NK cells express a series of clonally distributed
HLA class I–specific killer inhibitory receptors (KIR)
that suppress the NK cytotoxicity upon engagement with
self HLA class I alleles (1–4). At least in the case of HLA-
C–specific receptors, an activating form (termed p50) has
also been identified. Upon interaction with appropriate
HLA-C alleles, p50 triggers the NK-mediated cytolytic ac-
tivity (5, 6). Therefore, HLA class I–specific receptors may
regulate the NK cell function both in a negative and a pos-
itive fashion. However, NK cells are known to efficiently
kill target cells that do not express HLA class I molecules,
thus implying the existence of triggering receptors for non-
HLA ligands. Since all NK cell clones kill HLA-negative
target cells (1–4, 7, 8), it is conceivable that triggering re-
ceptors for non-HLA ligands are broadly expressed in NK
cells. However, major variability exists in the susceptibility
of different HLA class I–negative target cells to NK-medi-
ated lysis (9, 10). This phenomenon may reflect a variable
expression of different non-HLA ligands. Moreover, cul-
ture in exogenous IL-2 greatly enhances the cytolytic activ-
ity of NK cells against HLA-negative target cells (11–13). A
possible explanation could be the de novo expression in
NK cells of triggering receptors specific for additional non-
HLA ligands. At present, little is known on the nature of the
triggering NK receptors or of their non-HLA ligands. Along
this line, we recently identified a novel triggering surface
molecule, termed p46, that is specifically expressed on all
resting and activated human NK cells (14). mAb-mediated
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masking of p46 molecules resulted in a low degree inhibi-
tion of NK cell–mediated lysis of some HLA-negative tar-
get cells (14). A possible interpretation of these data is that
p46 may contribute to the process of tumor cell lysis,
which, however, would require the cooperation of addi-
tional receptor–ligand interactions.
In this study, we describe a novel NK-specific molecule
termed NKp44 that, similar to p46, mediates triggering of
all NK cell clones. However, different from p46, NKp44 is
only expressed by activated NK cells, thus representing a
useful marker for their identification. More importantly,
NKp44 appears to function as a receptor initiating a path-
way of NK cell triggering during the process of non-
MHC-restricted cytotoxicity by activated NK cells.
 
Materials and Methods
 
Antibodies.
 
The following mAbs were produced in our lab:
JT3A (IgG
 
2
 
a anti-CD3); c127 (IgG
 
1
 
 anti-CD16); KD1 (IgG
 
2
 
a
anti-CD16); c218 (IgG
 
1
 
 anti-CD56); A6-220 (IgM anti-CD56);
c227 (IgG1, anti-CD69); BAB281 (IgG1, anti-p46); and FES172
(IgG
 
2
 
a anti-p50.3). mAbs D1.12 (IgG
 
2
 
a anti–HLA-DR), HP2.6
(IgG
 
2
 
a anti-CD4), and B9.4 (IgG
 
2
 
b anti-CD8) were provided by
Drs. R.S. Accolla (Università di Pavia, Pavia, Italy), P. Sanchez-
Madrid (Hospital de la Princesa, Madrid, Spain), and B. Malissen
(Centre de Immunologie INSERM/CNRS, Marseille, France).
The 24-31 mAb (IgG1, anti-CD154/CD40L) was purchased from
Ancell (Bayport, MN), and the Gi9 mAb (IgG1, anti-CD49b/
VLA.2) was purchased from Immunotech (Marseille, France).
 
Production of Z231 mAb and Flow Cytofluorometric Analysis.
 
Z231 mAb (IgG1) was obtained by immunizing a 5-wk-old
BALB/c mouse with the NK clone SA260. Analysis of the cell
distribution of NKp44 molecules was performed by using one- or
two-color fluorescence cytofluorometric analysis (FACScan
 
Ò
 
,
Becton Dickinson, San Jose, CA), as previously described (15).
 
Purification of Polyclonal or Clonal NK or T Cell Populations and
Cytolytic Activity.
 
PBMCs were depleted of plastic-adherent
cells. To obtain NK cell–enriched lymphocyte populations, PBMCs
were incubated with anti-CD3 (JT3A) and anti-CD4 (HP2.6)
mAbs for 30 min at 4
 
8
 
C followed by treatment with goat anti–
mouse–coated Dynabeads (Dynal, Oslo, Norway) for 30 min at
4
 
8
 
C. The resulting CD3
 
2
 
 lymphocyte populations, containing
 
z
 
1% CD3
 
1
 
 cells, 20–30% HLA-DR
 
1
 
 cells, and 70–80% CD56
 
1
 
cells, were cultured in rIL-2 (Cetus Corp., Emeryville, CA). To
obtain polyclonally activated T cell–enriched lymphocyte popu-
lations, PBMCs were stimulated with 0.1% (vol/vol) PHA
(GIBCO Ltd., Paisley, Scotland) for 24 h and then cultured in
rIL-2. T or NK clones were obtained by limiting dilution, as pre-
viously described (15). Polyclonally activated cell cultures con-
taining both NK and T cells, obtained by culturing PBMCs in
the presence of irradiated H9 cell line and rIL-2, were used for
the analysis of NKp44 expression in resting or activated CD3
 
1
 
and CD3
 
2
 
 cells at various time intervals. The cytolytic activity
was assessed in a 4-h 
 
51
 
Cr–release assay (15) in which effector cells
were tested against the following (Fc
 
g
 
R
 
2
 
) human cell lines: A549
(lung adenocarcinoma), LCL 721.221 (B-EBV), RPMI 8866 (B-
EBV), and IGROV (ovarian carcinoma) at the indicated E/T ra-
tio. In redirected killing assays, target cells were represented by
the (Fc
 
g
 
R
 
1
 
) murine mastocytoma P815 cell line.
 
Biochemical Characterization of the NKp44 Molecules.
 
Cyanogen bro-
Figure 1. Functional and molecular
characteristics of NKp44 surface mole-
cule. (a) Triggering of cytolytic activity.
Four representative NK clones, derived
from two donors, were analyzed in a re-
directed killing assay against the FcgR1
P815 target cells either in the absence
(u) or presence of Z231 (j), anti-CD16
( ), anti-p46 ( ), anti-CD56 ( ), anti-
CD69 ( ), or anti-CD40L ( ) mAbs at
a 5:1 E/T ratio. All these mAbs are
IgG1. Clones MA4 and MA5 were
CD40L2, whereas clones MX340 and
MX310 were CD40L1. (b) Biochemical
characteristics. A 125I-surface labeled
polyclonal NK population, derived from donor LM, was immunoprecipitated with Z231 (lanes A and E), anti-CD69 (lanes B and F), anti-CD16 (lanes
C and G) or BAB281 (lanes D and H) mAbs. Samples were analyzed in an 11% SDS-PAGE under nonreducing (lanes A–D) or reducing (lanes E–H)
conditions. (c) N-glycosidase F digestion. NKp44 (lanes A and B), CD69 (lanes C and D), CD16 (lanes E and F), or p46 (lanes G and H) molecules iso-
lated from the surface-labeled NK cell population shown in b were treated or not with N-glycosidase F. Samples were run in an 11% SDS-PAGE under
reducing conditions. 
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mide sepharose (Pharmacia Biotech, Piscataway, NJ)–coupled
Z231 or BAB281 mAbs or Sepharose–protein A–coupled KD1
and C227 mAbs were used to immunoprecipitate specific mole-
cules from 1% NP40 lysates of cells surface-labeled with 
 
125
 
I (Du-
Pont-NEN, Wilmington, DE) as previously described (5, 15).
Immunoprecipitates were analyzed by discontinuous SDS-
PAGE. Specific bands were cut out from dried gel and eluted
proteins were used for 
 
N
 
-glycosidase F digestion (Boehringer
Mannheim, GmbH, Mannheim, Germany) (5, 16). For two-dimen-
sional peptide mapping analysis, the purified proteins were di-
gested with pepsin and peptides were analyzed by electrophoresis
in the first dimension (Multiphor II, Pharmacia Biotech), fol-
lowed by chromatography in the second dimension (5, 16).
 
Biochemical Characterization of the p46- and NKp44-associated
Molecules.
 
10
 
8
 
 NK cells were stimulated or not with 100 
 
m
 
M
Na-pervanadate (NaV, 10
 
9
 
, 37
 
8
 
C), washed twice in cold PBS,
and lysed in PLB (50 mM Tris-HCl, pH 8, 15 mM NaCl, 1%
Digitonin, and phosphatase and protease inhibitors) (45
 
9
 
, 4
 
8
 
C).
Lysates were immunoprecipitated with various mAbs for 1 h at
4
 
8
 
C. Immunoprecipitates were washed twice in PLB and eluted
samples were analyzed in 15% discontinuous SDS-PAGE under
reducing conditions. Proteins were transferred to Immobilon P
(Millipore Corp., Bedford, MA), and the membranes were satu-
rated with 5% BSA and probed with TIA/2 (anti-CD3
 
z
 
 mAb,
provided by Dr. B. Malissen), followed by goat anti–mouse-
horseradish peroxidase (HRPO; DAKO A/S, Glostrup, Den-
mark) or with PY20-HRPO (antiphosphotyrosine [anti-PTyr]
mAb; Transduction Laboratories, Lexington, KY). The Renais-
sance Chemiluminescence Kit (New England Nuclear, Boston,
MA) was used for detection.
 
Results and Discussion
 
Identification of a Novel 44-kD Triggering Surface Molecule
Selectively Expressed by Activated NK Cells.
 
Mice were im-
munized with the NK cell clone SA260 (surface pheno-
type: CD3
 
2
 
, CD16
 
1
 
, p46
 
1
 
, p70
 
1
 
, NKG2A
 
1
 
). After cell fu-
sion, an mAb termed Z231 was selected on the basis of its
ability to induce lysis of the Fc
 
g
 
R
 
1
 
 P815 target cells by a
panel of NK cell clones. The magnitude of cytolysis in-
duced by Z231 mAb in this redirected killing assay was
comparable to that induced by anti-CD16 or by the anti-
p46 mAb BAB281 (Fig. 1 
 
a
 
). Cell lysates, obtained from
IL-2–cultured, polyclonal NK cells that had been surface
labeled with 
 
125
 
I, were immunoprecipitated with Z231
mAb and analyzed by SDS-PAGE. A broad band of 
 
z
 
44-
kD could be identified both under reducing and nonreduc-
ing conditions (Fig. 1 
 
b
 
). The mobility of this molecule
(hereafter termed NKp44) was slightly modified by treat-
ment with 
 
N
 
-glycosidase F (Fig. 1 
 
c
 
). On the other hand,
treatment with neuraminidase followed by 
 
0
 
-glycanase had
no effect (data not shown). These data suggest that NKp44
may represent a molecule with a low degree of glycosyla-
tion.
Cytofluorimetric analysis revealed that NKp44 was ex-
pressed on virtually 100% of cells in activated polyclonal
NK cell populations (Fig. 2, box 
 
A
 
). Moreover, it was ex-
pressed in all NK cell clones analyzed. Fig. 2 (boxes 
 
B–E
 
)
shows four representative clones that illustrate the hetero-
geneity in the levels of NKp44 expression among different
clones. On the other hand, none of the numerous T cell
clones or polyclonal T cell populations analyzed expressed
NKp44 (Fig. 2, boxes 
 
F–L
 
). This was also true for selected
T cell clones (either TCR-
 
a
 
/
 
b
 
1
 
 or -
 
g
 
/
 
d
 
1
 
) expressing NK
cell markers including CD56, CD16, and KIRs (p58, p70,
or CD94/NKG2A). In addition, Z231 mAb did not stain
fresh PBMCs (isolated from different donors), granulocytes,
monocyte/macrophages, enriched T, B, or NK cells iso-
lated from peripheral blood, EBV-induced B cell lines, or
various nonhematopoietic cell lines (data not shown).
These data indicate that NKp44 is specifically expressed by
activated NK cells, thus differing from other molecules
such as p46 or CD16, which are expressed also in resting
NK cells. We next analyzed the surface expression of
NKp44 in unfractionated PBMCs cultured in IL-2. The
expression of NKp44 or other informative markers includ-
ing CD56, p46, CD69, and VLA-2 was analyzed at various
time intervals by double fluorescence against CD3. As
shown in Fig. 2 (
 
day 0
 
), at the onset of the culture NKp44
molecules were undetectable in both CD3
 
1
 
 and CD3
 
2
 
cells. After 10 d of culture, NKp44 was expressed by a por-
tion of CD3
 
2
 
 cells, whereas after 20 d, virtually all CD3
 
2
 
cells were NKp44
 
1
 
. No expression of NKp44 could be
detected in CD3
 
1
 
 T cells even after 30 d of culture (data
not shown). These data support the notion that NKp44
represents a novel marker of cell activation specifically ex-
pressed by NK cells. In agreement with previous data, the
other markers of cell activation, used for comparison, were
not confined to NK cells (17, 18). Thus, CD69 (Fig. 2) and
VLA-2 (data not shown) were expressed both in CD3
 
1
 
 and
CD32 cultured cells. In addition, CD69 reached maximal
expression after 24–48 h of culture (17), whereas expres-
sion of NKp44 only started after 3 d and progressively in-
creased thereafter (data not shown). In agreement with the
data that NKp44 is not expressed in fresh NK cells, mAb
Z231 failed to trigger target cell lysis by fresh CD32 cells in
a redirected killing assay. Increments in cytolytic activity
induced by Z231 mAb paralleled the progressive expres-
sion of NKp44 in cultured NK cells. Moreover, triggering
of cytolytic activity in a redirected killing assay was detect-
able only by using the intact mAb and not the F(ab9)2 frag-
ment (data not shown). This data indicates that NKp44 re-
quires efficient cross-linking to induce NK cell triggering.
Comparative Analysis between NKp44 and p46 Molecules.
Both the finding that NKp44 mediates triggering of NK
cell cytotoxicity and the finding that its expression is con-
fined to NK cells are reminiscent of the previously de-
scribed p46 molecule. The two molecules also display a
similar molecular mass (44 and 46 kD, respectively). In ad-
dition, as with p46, cross-linking of NKp44 led to Ca21
mobilization and lymphokine (TNF-a and IFN-g) release
in cloned NK cells (data not shown). A major difference
between the two molecules is that NKp44 is expressed only
upon NK cell activation. However, the possibility exists
that the epitope recognized by the Z231 mAb, although
carried by p46 molecules, may be exposed only upon cell
activation. To verify this possibility, 125I-labeled cell lysates
from either polyclonal or clonal (IL-2–cultured) NK cell2068 Triggering Natural Killer Cell Receptors
populations were precleared with anti-p46 mAb followed
by immunoprecipitation with anti-NKp44 mAb (and vice
versa). These experiments clearly indicated that the two
molecules were distinct (Fig. 3 a). These data were further
confirmed by two-dimensional peptide map analysis: as
shown in Fig. 3 b, none of the spots visualized in the
NKp44 map correspond to those of the p46 map and vice
versa.
NKp44 and -p46 Are Associated with Different Signal-trans-
ducing Molecules. In human NK cells, triggering receptors
such as CD16 or p50 (i.e., the activating forms of the
HLA-C–specific receptors; references 5, 6, 16) are coupled
Figure 2. Expression of NKp44 molecules in freshly isolated or cultured polyclonal and clonal NK or T cell populations. (top) A polyclonal NK cell
population (A), NK clones (B–E), a polyclonal T population (F), TCR-g/d1 (G), or TCR-a/b1 (H) T cell clones or TCR-g/d1 p58.21(I) and TCR-
a/b1 p701 (L) T cell clones were analyzed by immunofluorescence and FACSÒ analysis for surface expression of NKp44 molecules. (bottom) Freshly iso-
lated PBMCs were cultured in the presence of the irradiated H9 cell line and rIL-2 and analyzed by two-color immunofluorescence and FACSÒ analysis
at various time intervals for the expression of NKp44, CD56, p46, and CD69 surface molecules in combination with CD3 molecules. Cells were stained
with mAbs to the indicated molecules followed by FITC- or PE-conjugated isotype-specific goat anti–mouse second reagents. The contour plots were
divided into quadrants representing unstained cells (lower left), cells with only red fluorescence (upper left), cells with red and green fluorescence (upper
right), and cells with only green fluorescence (lower right).2069 Vitale et al.
to the intracytoplasmic transduction machinery via the as-
sociation with polypeptide subunits characterized by the
presence of immunoreceptor tyrosine-based activation mo-
tifs (ITAMs). CD16 associates with CD3z/FceRIg poly-
peptides (19, 20), whereas p50 molecules have recently
been shown to be part of a multimeric complex formed by
the association of these receptors with a newly identified
transducing molecule, termed KARAP/DAP12 (21, 22).
Both CD3z and KARAP/DAP12 molecules are tyrosine
phosphorylated after engagement of the associated recep-
tors. We analyzed whether NKp44 and p46 molecules
were associated with one or another signal-transducing
molecules. Cell lysates derived from NK bulk populations,
stimulated or not with Na-pervanadate, were immunopre-
cipitated with anti-NKp44, anti-p46, anti-p50.3, or anti-
CD16 mAbs; samples were analyzed in SDS-PAGE, trans-
ferred to PVDF membranes, and then immunoblotted with
anti-CD3z (Fig. 4 a) or anti-PTyr (Fig. 4 b) mAbs. No ty-
rosine phosphorylation of either p46 or NKp44 molecules
could be detected under these experimental conditions
(data not shown). On the other hand, as shown in Fig. 4 a,
p46, like CD16, was associated with CD3z molecules that
became tyrosine phosphorylated upon cell stimulation (Fig.
4  b). On the contrary, NKp44 did not associate with
CD3z molecules (Fig. 4 a). However, after stimulation, ty-
rosine phosphorylated molecules displaying a molecular
mass of z14–16 kD could be detected in NKp44 immuno-
precipitates (Fig. 4 b). These molecules displayed a molecu-
lar mass similar to the p50.3-associated KARAP/DAP12
molecules (Fig. 4 b). In addition, the 14–16-kD NKp44-
associated molecules were still detectable after extensive
preclearing with anti-CD3z/FceRIg Abs. This experiment
ruled out the possibility that the NKp44-associated 14–16-
kD tyrosine phosphorylated molecules were either CD3z
or FceRIg, and suggested that they correspond to the re-
cently identified KARAP/DAP12 molecules.
NKp44 Is Involved in NK Cell Activation during the Process
of Non-MHC-restricted Cytotoxicity. Since NKp44 repre-
sents a triggering surface molecule that is selectively ex-
pressed by activated NK cells, it is possible that it represents
a receptor involved in the process of non-MHC-restricted
tumor cell lysis by activated NK cells. To analyze this pos-
sibility, (NKp441) NK cell clones were selected for their
ability to kill a panel of (FcgR2) human target cell lines.
Selected clones were next assessed for cytotoxicity either in
the presence or absence of Z231 mAb. Although in the ab-
sence of mAb all targets were efficiently lysed, in the pres-
ence of Z231 mAb a minor inhibitory effect was detectable
against the A549 (lung adenocarcinoma), RPMI 8866, and
LCL 721.221 (EBV-transformed B cell lines) target cells
Figure 3. Comparison between NKp44 and p46 molecules. (a) Pre-
clearing experiments. The 125I-surface labeled NK cell population derived
from donor KK was immunoprecipitated three times with Z231 (lanes A–C)
or BAB281 (lanes E–G). The NKp44 or p46 precleared lysates were then
immunoprecipitated with BAB281 (lane D) or Z231 (lane H) mAbs, re-
spectively. Samples were analyzed in an 11% SDS-PAGE under reducing
conditions. (b) Peptide mapping analysis of NKp44 and p46 molecules.
125I-labeled NKp44 (A) or p46 (B) molecules were purified from the
polyclonal NK cell population KK. Proteins were digested with pepsin
and peptides were analyzed by electrophoresis in the first dimension fol-
lowed by chromatography in the second dimension.
Figure 4. Association of p46 and
NKp44 with immunoreceptor tyrosine-
based activation motif–bearing mole-
cules. (a) Cell lysates derived from a
polyclonal NK cell population were im-
munoprecipitated with mAbs to the in-
dicated molecules. Samples were run in
a 15% SDS-PAGE under reducing con-
ditions, transferred to PVDF mem-
branes, and probed with anti-z mAb. (b)
Cell lysates derived from a polyclonal
NK cell population unstimulated (NaV2)
or stimulated (NaV1) with 100 mM Na-pervanadate, were immunoprecipitated with mAbs to the indicated molecules. Samples were analyzed in a 15%
SDS-PAGE under reducing conditions, transferred to PVDF membranes, and probed with anti-PTyr mAb.2070 Triggering Natural Killer Cell Receptors
(Fig. 5). A similar inhibitory effect was obtained with the
anti-p46 mAb BAB281. These data suggested that NKp44
and p46 molecules could cooperate in the process of NK
cell triggering, resulting in killing of A548, 221, and 8866
cells. To assess this possibility, anti-NKp44 and anti-p46
mAbs were used in combination. Indeed, a sharp inhibition
of target cell lysis was obtained (Fig. 5), thus suggesting that
the two molecules may function as receptors that act syner-
gistically in the process of non-MHC-restricted lysis by ac-
tivated NK cells. No inhibition of cytotoxicity was de-
tected in the presence of a control, isotype-matched antibody
(CD56, IgG1; data not shown) or in the presence of an anti-
body directed to another triggering molecule expressed by
NK cells after activation (anti-CD69, IgG1). In addition,
the inhibitory effects of anti-NKp44 or p46 mAb were not
increased when used in combination with anti-CD69 mAb
(Fig. 5).
Remarkably, killing of IGROV cells was not affected by
anti-p46 and anti-NKp44 mAbs even when used in combi-
nation. This may be explained as follows. (a) IGROV cells
do not express, or express in low density, the ligands recog-
nized by NKp44 or p46 receptors. (b) IGROV cells do ex-
press the p46 and NKp44 ligands; however, their recog-
nition by the corresponding NK receptors does not
contribute significantly to NK cell triggering. In any case, it
is conceivable that IGROV cells express additional ligands
for still undefined triggering NK receptors. Interactions be-
tween these receptors and their ligands would play a pre-
dominant role in the NK-mediated lysis of these target
cells. These data are consistent with the idea that NK cell
triggering may be mediated by several different receptor–
ligand interactions (23). Expression, lack of expression, or
even different levels of expression of given ligands for trig-
gering receptors may influence the susceptibility of tumor
cells to NK cell–mediated killing. In this context, the use
of target cells such as A549, 8866, and 221 gave useful re-
sults in this study in identifying the role of NKp44 mole-
cule as a triggering receptor in the NK–target cell interac-
tions.
Regarding the still undefined ligand for NKp44, the use
as target cells of the HLA class I2 221 cell line transfected
or not with different HLA class I alleles ruled out the possi-
bility that HLA class I molecules could trigger NK cells via
NKp44 (data not shown).
The NK-mediated target cell lysis may also depend upon
the type (and density) of receptors on different effector
cells. For example, since NKp44 molecule is selectively ex-
pressed by activated NK cells, it is conceivable that it may
play at least a partial role in the enhanced cytolytic activity
of these cells. Although both NKp44 and p46 are homoge-
neously expressed on activated NK cells, it is possible that
other triggering receptors may be expressed selectively by
subsets of NK cells (as is the case for the HLA-C–specific
p50 molecules).
In humans, other surface molecules, including CD69
(24) and CD40L (25), have been reported to be involved in
triggering of cytotoxicity mediated by in vitro activated
NK cells. However, these molecules are not NK-specific
and do not appear to interfere with non-MHC-restricted
target cell lysis. Regarding the CD40L, we found that it is
expressed only by some NK cell clones and we failed to in-
duce any substantial NK cell triggering in redirected killing
assays (Fig. 1 a).
Gp42, a 42-kD, NK-specific rat molecule, is reminiscent
of NKp44 (26, 27). Indeed, it was detected in IL-2–induced
NK cells and was shown to trigger cytotoxicity mediated
by the RNK-16 rat NK cell line. However, Gp42 failed to
activate IL-2–induced NK cells. In addition, Gp42 is a gly-
cosylphosphatidylinositol-anchored surface molecule, which
is not the case for GPI NKp44 since its surface expression is
not modified by cell treatment with phosphatidylinositol-
specific phospholipase (data not shown).
In conclusion, this study revealed a novel surface mole-
cule selectively expressed by human activated NK cells that
appears to function as a triggering receptor involved in
non-MHC-restricted cytotoxicity by activated NK cells.
The identification of NKp44 as a putative NK receptor
may lead to a more precise definition of the nature of the
receptor–ligand interactions occurring in the NK-mediated
lysis of tumor cells.
Figure 5. Inhibition of non-MHC-restricted cytotoxicity by mAb-
mediated masking of NKp44 and p46 molecules. The representative NK
clone MID1 was analyzed for cytolytic activity against the indicated
FcgR2 target cell lines either in the absence or presence of anti-p46, anti-
NKp44, anti-CD69, or a combination of anti-p46 1 anti-NKp44, anti-
p46 1 anti-CD69, or anti-NKp44 1 anti-CD69 mAbs. Percentage of ly-
sis 6 SD at the 8:1 E/T ratio is shown. Each bar represents the mean of
five different experiments.2071 Vitale et al.
We thank Mrs. Cinzia Miriello for typing the manuscript.
This work was supported by grants awarded by the Associazione Italiana per la Ricerca sul Cancro
(A.I.R.C.), Istituto Superiore di Sanità (I.S.S.), Consiglio Nazionale delle Ricerche (C.N.R.), and Progetto
Finalizzato Applicazioni Cliniche per la Ricerca Oncologica.
Address correspondence to Lorenzo Moretta, Centro Biotecnologie Avanzate, Largo R. Benzi 10, 16132
Genova, Italy. Phone: 39-10-57-37-217; FAX: 39-10-35-41-23; E-mail: miriello@sirio.cba.unige.it
Received for publication 3 March 1998 and in revised form 8 April 1998.
References
1. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni,
M.C. Mingari, and L. Moretta. 1996. Receptors for HLA-
class I molecules in human natural killer cells. Annu. Rev. Im-
munol. 14:619–648.
2. Moretta, A., R. Biassoni, C. Bottino, D. Pende, M. Vitale,
A. Poggi, M.C. Mingari, and L. Moretta. 1997. Major histo-
compatibility complex class I–specific receptors on human
natural killer and T lymphocytes. Immunol. Rev. 155:105–
117.
3. Lanier, L.L. 1997. NK cells: from no receptors to too many.
Immunity. 6:371–378.
4. Valiante, N.M., K. Lienert, H.G. Shilling, B.J. Smits, and P.
Parham. 1997. Killer cell receptors: keeping pace with MHC
class I evolution. Immunol. Rev. 155:155–164.
5. Moretta, A., S. Sivori, M. Vitale, D. Pende, L. Morelli, R.
Augugliaro, C. Bottino, and L. Moretta. 1995. Existence of
both inhibitory (p58) and activatory (p50) receptors for
HLA-C molecules in human natural killer cells. J. Exp. Med.
182:875–884.
6. Biassoni, R., C. Cantoni, M. Falco, S. Verdiani, C. Bottino,
M. Vitale, R. Conte, A. Poggi, A. Moretta, and L. Moretta.
1996. The human leukocyte antigen (HLA)-C–specific “acti-
vatory” or “inhibitory” natural killer cell receptors display
highly homologous extracellular domains but differ in their
transmembrane and intracytoplasmic portions. J. Exp. Med.
183:645–650.
7. Ciccone, E., D. Pende, M. Vitale, L. Nanni, C. Di Donato,
C. Bottino, L. Morelli, O. Viale, A. Amoroso, A. Moretta,
and L. Moretta. 1994. Self class I molecules protect normal
cells from lysis mediated by autologous natural killer cells.
Eur. J. Immunol. 24:1003–1006.
8. Valiante, N.M., M. Uhrberg, H.G. Shilling, K. Lienert-
Weidenbach, K.L. Arnett, A. D’Andrea, J.H. Phillips, L.L.
Lanier, and P. Parham. 1997. Functionally and structurally
distinct NK cell receptor repertoires in the peripheral blood
of two human donors. Immunity. 7:739–751.
9. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J.J. Perez-Villar,
M. Lopez-Botet, M. Duggan-Keen, and P.L. Stern. 1997.
Implications for immunosurveillance of altered HLA class I
phenotypes in human tumours. Immunol. Today. 18:89–95.
10. Höglund, P., C. Öhlen, E. Carbone, L. Franksson, H.G.
Ljunggren, A. Latour, B. Koller, and K. Kärre. 1991. Recog-
nition of b2-microglobulin–negative (b2m2) T cell blasts by
natural killer cells from normal but not from b2m2 mice:
nonresponsiveness controlled by b2m-bone marrow in chi-
meric mice. Proc. Natl. Acad. Sci. USA. 88:10332–10336.
11. Robertson, M.J., and J. Ritz. 1992. Role of IL-2 receptors in
NK cell activation and proliferation. In NK Cell Mediated
Cytotoxicity: Receptors, Signaling and Mechanism. E. Lot-
zova and R.B. Herberman, editors. CRC Press, Boca Raton,
FL. 183–206.
12. Ferrini, S., S. Miescher, M.R. Zocchi, V. Von Fliedner, and
A. Moretta. 1987. Phenotypic and functional characterization
of recombinant interleukin-2 (rIL-2)-induced activated killer
cells. Analysis at the population and clonal levels. J. Immunol.
138:1297–1302.
13. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Im-
munol. 47:187–376.
14. Sivori, S., M. Vitale, L. Morelli, L. Sanseverino, R. Au-
gugliaro, C. Bottino, L. Moretta, and A. Moretta. 1997. p46,
a novel natural killer cell–specific surface molecule that medi-
ates cell activation. J. Exp. Med. 186:1129–1136.
15. Moretta, A., G. Tambussi, C. Bottino, G. Tripodi, A. Merli,
E. Ciccone, G. Pantaleo, and L. Moretta. 1990. A novel sur-
face antigen expressed by a subset of human CD3-CD161
natural killer cells. Role in cell activation and regulation of
cytolytic function. J. Exp. Med. 171:695–714.
16. Bottino, C., S. Sivori, M. Vitale, C. Cantoni, M. Falco, D.
Pende, L. Morelli, R. Augugliaro, G. Semenzato, R. Biassoni,
et al. 1996. A novel surface molecule homologous to the p58/
p50 family of receptors is selectively expressed on a subset of
human natural killer cells and induces both triggering of cell
functions and proliferation. Eur. J. Immunol. 26:1816–1824.
17. Cebriàn, M., E. Yague, M. Rincòn, M. Lòpez-Botet, M.O.
De Landàzuri, and F. Sànchez-Madrid. 1988. Triggering of T
cell proliferation through AIM, an activation inducer mole-
cule expressed on activated human lymphocytes. J. Exp. Med.
168:1621–1637.
18. Hemler, M.E. 1990. VLA proteins in the integrin family:
structure, functions and their role on leukocytes. Annu. Rev.
Immunol. 8:365–400.
19. Lanier, L.L., G. Yu, and J.H. Phillips. 1989. Co-association
of CD3z with a receptor (CD16) for IgG Fc on human natu-
ral killer cells. Nature. 342:803–805.
20. Vivier, E., N. Rochet, J.P. Kochan, D.H. Presky, S.F. Schloss-
man, and P. Anderson. 1991. Structural similarities between
Fc receptors and T cell receptors: expression of the g subunit
of the FceRI in human T cells, NK cells and thymocytes. J.
Immunol. 147:4263–4270.
21. Olcese, L., A. Cambiaggi, G. Semenzato, C. Bottino, A.
Moretta, and E. Vivier. 1997. Human killer cell activatory
receptors for MHC class I molecules are included in a multi-
meric complex expressed by natural killer cells. J. Immunol.
158:5083–5086.
22. Lanier, L.L., B.C. Corliss, W. Jun, C. Leong, and J.H. Phil-
lips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based
activation motif is involved in activating NK cells. Nature.
391:703–707.2072 Triggering Natural Killer Cell Receptors
23. Lanier, L.L., B. Corliss, and J.H. Phillips. 1997. Arousal and
inhibition of human NK cells. Immunol. Rev. 155:145–154.
24. Moretta, A., A. Poggi, D. Pende, G. Tripodi, A.M. Orengo,
N. Pella, R. Augugliaro, C. Bottino, E. Ciccone, and L.
Moretta. 1991. CD69-mediated pathway of lymphocyte acti-
vation. Anti-CD69 mAbs trigger the cytolytic activity of dif-
ferent lymphoid effector cells with the exception of cytolytic
T lymphocytes expressing TCR a/b. J. Exp. Med. 174:
1393–1398.
25. Carbone, E., G. Ruggiero, G. Terrazzano, C. Palomba, C.
Manzo, S. Fontana, H. Spitz, K. Karre, and S. Zappacosta. 1997.
A new mechanism of NK cell cytotoxicity activation: the
CD40–CD40 ligand interaction. J. Exp. Med. 185:2053–2060.
26. Imboden, J.B., E.C. Eriksson, M. McCutcheon, C.W. Rey-
nolds, and W.E. Seaman. 1989. Identification and character-
ization of a cell-surface molecule that is selectively induced
on rat lymphokine-activated killer cells. J. Immunol. 143:
3100–3103.
27. Seaman, W.E., E.C. Niemi, M.R. Stark, R.D. Goldfien, A.S.
Pollock, and J.B. Imboden. 1991. Molecular cloning of gp42,
a cell-surface molecule that is selectively induced on rat natu-
ral killer cells by interleukin 2: glycolipid membrane anchor-
ing and capacity for transmembrane signaling. J. Exp. Med.
173:251–260.